Zydus Lifesciences Ltd

BSE : ZYDUSLIFE12 Feb 2025
Pharmaceuticals
-7.45 (-0.79%)
Lowest Today
Highest Today
Today’s Open
Prev. Close
52 Week High
52 Week Low
To Invest in Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
Pharmaceuticals
BSE : ZYDUSLIFE12 Feb 2025
-7.45 (-0.79%)
1D
1M
6M
1Y
5Y
All

Zydus Lifesciences Ltd - Share Price & Details

Traded Volume
Market Cap(Cr)
Avg Traded Price
1 Year return
9.94%
Upper Circuit
Lower Circuit
P/E TTM
21.5
P/B Ratio
5.25
Traded Value(Cr)
0.02
EPS TTM
43.46
Book value
Dividend
0.32%

Invest in Zydus Lifesciences Ltd at ZERO Brokerage for 30 days

Price Performance

-3.27 %
1 Wk
-3.35 %
1 M
-2.78 %
3 M
9.94 %
1 Y
-3.29 %
YTD

Traded Volume Movement

Technical Details

Support 3
897
Support 2
909
Support 1
922
Pivot Point :
934
Resistance 1
947
Resistance 2
959
Resistance 3
972

Reports

Peer Comparison

Scrip NamePriceDaily ChangeM.Cap (Cr)1 Year Returns %P/E (TTM)PB Ratio
Zydus Lifesciences Ltd
₹934.20(-7.45/-0.79%)
934.20-7.4594,002.389.9421.505.25
Astrazeneca Pharma India Ltd
₹7,494.65(+27.80/0.37%)
7,494.65+27.8018,736.6337.10145.5627.58
Bliss GVS Pharma Ltd
₹138.20(-5.35/-3.73%)
138.20-5.351,456.2226.3117.951.42
Abbott India Ltd
₹28,769.45(-367.50/-1.26%)
28,769.45-367.5061,135.082.3945.8117.36
Amrutanjan Health Care Ltd
₹620.90(-13.50/-2.13%)
620.90-13.501,795.06-0.0337.776.03
Ambalal Sarabhai Enterprises Ltd
₹50.15(-0.01/-0.02%)
50.15-0.01384.32-15.9943.618.53

About Zydus Lifesciences Ltd

Zydus Lifesciences Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 94002.38 crores. It has reported a sales of Rs. 2408.9 crores and a net profit of Rs. 470.6 crores for the quarter ended December 2018. The company management includes Pankaj R Patel, Pankaj R Patel,Sharvil P Patel,Mukesh M Patel,Apurva S Diwanji,Ganesh N Nayak,Bhadresh K Shah,Dhaval N Soni,Akhil A. Monappa,Upasana Konidela.,Shelina P. Parikh (Zydus Lifesciences Ltd) among others.
Chairman
Pankaj R Patel
Registered office
Zydus Corporate Park S No 536,Khoraj Sarkhej-Gandhinagar H/W,Ahmedabad,Gujarat,382481
FAX :91-079-26868337/26862365/26862366
Background
Incorporation Year1995
Face Value₹1
Market Lot1

Latest News

📢 Benchmark indices close marginally lower today; Nifty around 23,040

📈 Domestic benchmark indices closed on a flat note on 12 February 2025.
📢 At 3:30 PM, the Sensex declined 122.52 points or 0.16% at 76,171.08, and the Nifty was down by 26.55 points or 0.12% at 23,045.25.
📊Among sectoral, Nifty PSU Bank (⬆️0.84%) turned out to be the best performer while Nifty Auto (⬇️0.74%) saw considerable selling.
12 Feb 2025 | 03:45 PM

📢 Benchmark indices close marginally lower today; Nifty around 23,040

📈 Domestic benchmark indices closed on a flat note on 12 February 2025.
📢 At 3:30 PM, the Sensex declined 122.52 points or 0.16% at 76,171.08, and the Nifty was down by 26.55 points or 0.12% at 23,045.25.
📊Among sectoral, Nifty PSU Bank (⬆️0.84%) turned out to be the best performer while Nifty Auto (⬇️0.74%) saw considerable selling.
12 Feb 2025 | 03:45 PM

Godrej Industries Q3 net profit zooms 77% on solid chemicals

Business conglomerate Godrej Industries Ltd on Wednesday (February 12) reported a 76.9% year-on-year (YoY) jump in net profit at ₹188.2 crore in Q3FY24 compared to ₹106.4 crore a year ago. Revenue from operations surged 34.4% to ₹4,824.8 crore against ₹3,590 crore in the corresponding period of the preceding fiscal.
12 Feb 2025 | 06:48 PM

Force Motors Standalone December 2024 Net Sales at Rs 1,889.36 crore

Reported Standalone quarterly numbers for Force Motors are: Net Sales at Rs 1,889.36 crore in December 2024 up 11.69% from Rs. 1,691.56 crore in December 2023. Quarterly Net Profit at Rs. 110.06 crore in December 2024 up 16.17% from Rs. 94.74 crore in December 2023. EBITDA stands at Rs. 246.46 crore in December 2024 up 7.94% from Rs. 228.33 crore in December 2023.
12 Feb 2025 | 06:38 PM

Maxheights Standalone December 2024 Net Sales at Rs 0.17 crore

Reported Standalone quarterly numbers for Maxheights Infrastructure are: Net Sales at Rs 0.17 crore in December 2024 down 75.71% from Rs. 0.71 crore in December 2023. Quarterly Net Loss at Rs. 0.02 crore in December 2024 up 81.39% from Rs. 0.11 crore in December 2023. EBITDA stands at Rs. 0.07 crore in December 2024 up 800% from Rs. 0.01 crore in December 2023.
12 Feb 2025 | 06:36 PM

How to buy Zydus Lifesciences Ltd shares on nse?

To buy Zydus Lifesciences Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Zydus Lifesciences Ltd share price today?

The Zydus Lifesciences Ltd shares price on nse is Rs.934.2 today.

What is the market cap of Zydus Lifesciences Ltd shares on BSE ?

The company has a market capitalization of Rs.94002.38Cr

What is the PE & PB ratio of Zydus Lifesciences Ltd shares ?

PE is 21.5 and PB is 5.25

What is the 52 Week High and Low of Zydus Lifesciences Ltd shares?

Zydus Lifesciences Ltd stock price high: Rs.1323.9 Zydus Lifesciences Ltd stock price low: Rs.804

What is Zydus Lifesciences' stock forecast?

With a new 52-week high, the Zydus Lifesciences stock is expected to outperform in the near term. The average target as of May 11, 2023, is Rs. 521 – a 1.41% increase from the current price of Rs. 513.75.

What is Zydus Lifesciences stock's highest price ever?

The highest price ever for Zydus Lifesciences was Rs. 650.50 on 4th June 2021. 

What is the Zydus Lifesciences stock price target for 2024?

Zydus Lifesciences continues to build a robust product pipeline in innovative, branded generics, as well as genetics categories. Further, the operational efficiency is expected to drive better-than-industry growth in the DF segment. However, analysts at Motilal Oswal have reiterated a ‘neutral’ outlook on the stock, given limited upside from the current levels.

Does Zydus Lifesciences have a solid foundation?

Zydus Lifesciences has a solid foundation that has triggered its recent bullish run. It has a strong presence in the pharmaceutical industry and has been operating for several decades in the development, manufacturing, and marketing of a wide range of healthcare products, including pharmaceuticals, diagnostics, herbal products, and wellness products. With a recent FDA clearance on a pulmonary drug and better-than-expected Q3 profits, Zydus has shown stable and reliable growth. 

What is the Zydus Lifesciences stock dividend payout date?

Zydus Lifesciences is expected to pay its stock dividend in July. The company consistently paid dividends in July for the past two years.

What is the most recent Zydus Lifesciences stock news?

Zydus received the USFDA nod to manufacture and market drugs for osteoporosis, ulcer, blood pressure, heart disease, and pulmonary infections, and general anti-inflammatories. Furthermore, it is looking to sell its clinical research business for close to USD 200 million. 

Click here to see your activities